Premium
A clinician's experience of using the Cardiac Reader NT‐proBNP point‐of‐care assay in a clinical setting
Author(s) -
Alehagen U.,
Janzon M.
Publication year - 2008
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/j.ejheart.2008.01.005
Subject(s) - medicine , concordance , heart failure , roche diagnostics , natriuretic peptide , point of care testing , point of care , cardiology , intensive care medicine , pathology
The evaluation of natriuretic peptides has become increasingly valuable in a clinical setting, where information is often needed promptly. Objectives: To compare the usefulness of the recently released Roche Cardiac Reader® NT‐proBNP assay against the Roche Elecsys® NT‐proBNP laboratory system in a clinical setting. Design and results: Blood samples from 440 patients, who were either admitted with acute coronary syndromes or worsening heart failure, or who were heart failure outpatients, were evaluated. The relation between the two assays was analysed and the diagnostic concordance calculated. A good correlation was found between the assays ( r = 0.96, 95% CI: 0.94–0.97) with a diagnostic concordance of 93%. A separate analysis was performed in the range where most clinical decisions are made (60–3000ng/L), with a diagnostic concordance of 88%. The usefulness in a clinical setting where time is important was high. Conclusion: The Roche Cardiac Reader® NT‐proBNP assay has been evaluated in a clinical setting. The point‐of‐care method shows good results, although with a restricted analytical range, compared with the reference.